Ishita Drugs & Indus P/E Ratio
Current P/E Ratio
31.36
High Valuation
Very High - High growth expectations or significantly overvalued
Ishita Drugs & Indus P/E ratio. Ishita Drugs & Indus (ISHITADR) P/E ratio is 31.36 (High), EPS (TTM) ₹2.60, current price ₹79.83 on BSE — Very High - High growth expectations or significantly overvalued. For live price, revenue and the complete fundamental profile, see ISHITADR stock price BSE.
Current Valuation Metrics
P/E Ratio
31.36
Current Price
₹79.83
EPS (TTM)
₹2.60
Exchange
BSE
Valuation Signal
Signal
Overvalued
Sector Context
Sector Average
56.3
Sector Median
32.5
Sector Rank
#11 of 199
Sector Percentile
5.5%
ISHITADR P/E Ratio — Valuation Signal & Historical Context
Ishita Drugs & Indus P/E 31.36 — signal: Overvalued. Also explore ISHITADR share price charts to track price trends across different timeframes.
- Stock appears overvalued with PE of 31.36, suggesting caution for new investments
- Trading at discount to sector average PE of 56.3
ISHITADR vs Healthcare Peers — P/E Ratio Comparison
Ishita Drugs & Indus P/E 31.36 vs Healthcare average 56.3, median 32.5 — range 2.04–740.29.
Sector Average
56.3
Sector Median
32.5
Lowest P/E
2.04
Highest P/E
740.29
Companies
199
| Company | Symbol | P/E Ratio | Market Cap (₹ Cr) | Valuation |
|---|---|---|---|---|
| Sunrest Lifescience | SUNREST | 2.04 | ₹65 | Low |
| Murae Organisor | MURAE | 2.86 | ₹41 | Low |
| Phaarmasia | PHRMASI | 3.41 | ₹63 | Low |
| Sun Pharma Advanced Rese… | SPARC | 3.98 | ₹6,206 | Low |
| Dipna Pharmachem | DPL | 4.57 | ₹12 | Low |
| JFL Life Sciences | JFLLIFE | 4.88 | ₹66 | Low |
| GKB Ophthalmics | GKB | 5.88 | ₹32 | Low |
| Kabra Drugs | KABRADG | 6.09 | ₹44 | Low |
| Royal Sense | ROYAL | 6.58 | ₹47 | Low |
| Colinz Laboratories | COLINZ | 6.62 | ₹18 | Low |